ClinicalTrials.gg
TerminatedNCT04447404Updated Aug 5, 2022Results posted

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

A Phase 2 interventional study of DUR-928 and Placebo in SARS-CoV-2, sponsored by Durect. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Why this study was terminated
low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2

02

Conditions studied

  • SARS-CoV-2
03

In context

Lead sponsor

Durect is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

First submitted before Durect became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with moderate, severe, or early critical COVID-19 illness diagnosed by RT- PCR
  • Acute liver injury (including acute on chronic liver disease) or acute kidney injury or moderate COVID-19 pneumonia

Exclusion criteria

Exclusion Criteria:

  • Critical COVID-19 illness (MAP \< 60 mm Hg, on mechanical ventilator for ≥ 5 days)
  • On maintenance hemodialysis or peritoneal dialysis
  • C cirrhosis
  • Hepatorenal syndrome
  • Ascites and/or hepatic encephalopathy
  • History of end stage renal disease or CKD with \< 15 mL/min/1.73m2
  • Women who are pregnant or breast feeding
  • Receipt of other concomitant experimental therapies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    DUR-928

    Drug: DUR-928

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • IV infusion

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Composite Endpoint of Alive and Free of Organ Failure at Day 28

    Free of mechanical ventilation, free of renal replacement therapy and free of acute liver failure

    Time frame: Day 28

Secondary outcomes

  1. Alive at Days 28 and 60

    Time frame: Day 28 and Day 60

  2. Alive, Out of ICU, at Day 28

    Time frame: Day 28

  3. Alive, Out of Hospital, at Days 28 and 60

    Time frame: Day 28 and Day 60

07

Results

Posted Aug 5, 2022
Limitations and caveats
Early study termination led to small number (n=2) of subjects and in one treatment group.

Participant flow

Participant flow — Overall Study
MilestoneDUR-928Placebo
Started20
Completed00
Not completed20
Withdrew: Death20

Outcome measures

PrimaryComposite Endpoint of Alive and Free of Organ Failure at Day 28

Free of mechanical ventilation, free of renal replacement therapy and free of acute liver failure

Time frame:
Day 28
Reported as:
Count of participants · Participants
Composite Endpoint of Alive and Free of Organ Failure at Day 28
ParticipantsDUR-928Placebo
Composite Endpoint of Alive and Free of Organ Failure at Day 2800
SecondaryAlive at Days 28 and 60
Time frame:
Day 28 and Day 60
Reported as:
Count of participants · Participants
Alive at Days 28 and 60
ParticipantsDUR-928Placebo
Alive at Days 28 and 6000
SecondaryAlive, Out of ICU, at Day 28
Time frame:
Day 28
Reported as:
Count of participants · Participants
Alive, Out of ICU, at Day 28
ParticipantsDUR-928Placebo
Alive, Out of ICU, at Day 2800
SecondaryAlive, Out of Hospital, at Days 28 and 60
Time frame:
Day 28 and Day 60
Reported as:
Count of participants · Participants
Alive, Out of Hospital, at Days 28 and 60
ParticipantsDUR-928Placebo
Alive, Out of Hospital, at Days 28 and 6000

Adverse events

Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DUR-9282/2 (100%)2/2 (100%)2/2 (100%)
Placebo———
Most frequent serious events
Most frequent serious events
EventDUR-928Placebo
Respiratory failureRespiratory, thoracic and mediastinal disorders1/2—
Brain InjuryNervous system disorders1/2—
Most frequent other events
Most frequent other events
EventDUR-928Placebo
PyrexiaGeneral disorders2/2—
HyperkalaemiaMetabolism and nutrition disorders2/2—
Deep Vein ThrombosisVascular disorders2/2—
HypotensionVascular disorders2/2—
AnaemiaBlood and lymphatic system disorders1/2—
BradycardiaCardiac disorders1/2—
Activated Partial Thromboplastin Time ProlongedInvestigations1/2—
HypokalaemiaMetabolism and nutrition disorders1/2—
HyponatraemiaMetabolism and nutrition disorders1/2—

Baseline characteristics

Study terminated early due to lack of enrollment.

Age, Categorical
Age, Categorical(Participants)DUR-928PlaceboTotal
<=18 years000
Between 18 and 65 years101
>=65 years101
Age, Continuous
Age, Continuous(years)DUR-928PlaceboTotal
Mean66.5 ± 16.26—66.5 ± 16.26
Sex: Female, Male
Sex: Female, Male(Participants)DUR-928PlaceboTotal
Female202
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DUR-928PlaceboTotal
Hispanic or Latino202
Not Hispanic or Latino000
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DUR-928PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White202
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Site 03
    Newark, New Jersey 07103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2021, 5 months.

Results were first posted in Aug 2022, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 25, 2020
StartActual
Sep 21, 2020
Primary completionActual
Mar 4, 2021
CompletionActual
Mar 4, 2021
Results first posted
Aug 5, 2022
Last update
Aug 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04447404
Lead sponsor
Durect
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Sep 21, 2020
Primary completion
Mar 4, 2021
Completion
Mar 4, 2021
Results posted
Aug 5, 2022
Last update
Aug 5, 2022

Study contacts

Robert Gordon, MD
study director · CTI Clinical Trial and Consulting Services

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larsucosterol

Start the discussion